康方生物(09926.HK)完成配售2355万股

Core Viewpoint - 康方生物 has successfully completed the primary placement agreement, with all conditions met as of September 4, 2025, resulting in the issuance of 23.55 million shares at a price of HKD 149.54 per share, which represents approximately 2.56% of the company's expanded issued share capital post-placement [1][1][1] Summary by Category Company Actions - 康方生物 announced the completion of the primary placement agreement, confirming that all conditions have been fulfilled [1] - A total of 23.55 million shares were placed at a price of HKD 149.54 per share [1] Financial Impact - The placement will increase the company's issued share capital by approximately 2.56% following the issuance of the placement shares [1]